New research raises urgent questions about fracture risk and bone loss in older adults taking popular weight-loss medications
New research raises urgent questions about fracture risk and bone loss in older adults taking popular weight-loss medications
For millions of Americans, GLP-1 medications like Ozempic and Wegovy have transformed the treatment of Type 2 diabetes and obesity. But a pair of new studies is adding a troubling asterisk — one that asks what these drugs may be quietly doing to bone.
Researchers now link GLP-1 therapy to a measurable increase in fracture risk, osteoporosis and gout, particularly in older patients. The findings do not challenge the drugs’ well-established benefits — but they are pushing bone health to the front of the prescribing conversation.
A Modest But Meaningful Risk
A February study in the Journal of Clinical Endocrinology & Metabolism tracked more than 46,000 adults aged 65 and older for nearly three years and found that those on GLP-1 medications faced an 11% higher risk of fragility fractures compared to patients on other diabetes drugs.
Fragility fractures — breaks triggered by minor falls or ordinary movement — carry serious consequences for the elderly, including hospitalization, loss of independence and higher mortality. Lead author Dr. Michal Kasher Meron, an endocrinologist at Meir Medical Center in Israel, noted that both aging and Type 2 diabetes are already independent risk factors for such fractures, making GLP-1 users in this cohort a particularly vulnerable group.
Kasher Meron also flagged a generational gap in the data: earlier research on younger patients using older GLP-1 formulations showed no elevated fracture risk. Today’s drugs are more potent, and they are increasingly reaching older adults — a population for whom the risk profile looks different.
GLP-1, Osteoporosis and a Broader Pattern
A separate analysis presented at the American Academy of Orthopaedic Surgeons’ annual meeting reinforced those concerns. Examining data from more than 146,000 adults with obesity and Type 2 diabetes, researchers found GLP-1 users had a 29% higher relative risk of osteoporosis over five years. Gout rates were also elevated — 7.4% among GLP-1 users versus 6.6% in nonusers — and osteomalacia, a softening of the bones, appeared at roughly twice the rate, though it remained rare in both groups.
That study has not yet been peer reviewed and, like the first, is observational — identifying associations rather than causes. Its lead author, Dr. John Horneff of the University of Pennsylvania, drew a striking parallel: the bone loss pattern resembles what astronauts experience in zero gravity, where the absence of mechanical load accelerates skeletal deterioration.
Why These GLP-1 Drugs May Weaken Bone
Several mechanisms are likely at play. Rapid weight loss reduces the mechanical load on the skeleton, which can prompt a decline in bone density. Suppressed appetite may also mean lower intake of calcium, vitamin D and protein — nutrients essential to bone strength. And the tissue breakdown that accompanies rapid weight loss can temporarily spike uric acid levels, a known trigger for gout.
What GLP-1 Patients and Doctors Should Do
Experts are clear: these findings are a call for vigilance, not a reason to abandon medications with proven cardiovascular and metabolic benefits. Kasher Meron’s guidance is straightforward — bone density screening should happen before starting GLP-1 therapy in older patients, not after a fracture forces the issue. Once on treatment, patients should prioritize nutrition and resistance training to protect both muscle and bone during weight loss.
Industry Response and Ongoing Scrutiny
Novo Nordisk, the maker of Ozempic and Wegovy, said it welcomes independent research and works closely with the FDA on safety. A spokesperson pointed to the drug’s current labeling as reflecting its known risk-benefit profile and emphasized semaglutide’s cardiovascular, kidney and liver benefits under medical supervision. The company also noted that osteoporosis develops over years through multiple intersecting factors — a reminder that untangling drug effects from underlying disease is rarely straightforward.
Still, as GLP-1 medications become one of the most prescribed drug classes in America, the urgency to understand their full impact only intensifies. Bone health, it turns out, may be the next chapter of that story.
Source: Fox News